ストックスクリーナーアプリを入手
19.34
3.15%
0.59
アフターアワーズ：
19.00
-0.34
-1.76%
前日終値:
$18.75
開ける：
$18.85
24時間の取引高:
696.52K
Relative Volume:
0.83
時価総額：
$1.14B
収益：
当期純損益:
$-883.08M
株価収益率:
-0.058
EPS:
-333.4782
ネットキャッシュフロー:
$-150.65M
1週間 パフォーマンス:
+1.10%
1か月 パフォーマンス:
-13.35%
6か月 パフォーマンス:
+23.97%
1年 パフォーマンス:
-36.00%
1日の値動き範囲:
$18.78
$20.25
1週間の範囲:
$18.55
$20.52
52週間の値動き範囲:
$6.50
$33.42
Vor Biopharma Inc Stock (VOR) Company Profile
Compare VOR vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
19.34 | 1.14B | 0 | -883.08M | -150.65M | -333.48 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-30 | 開始されました | Jefferies | Buy |
| 2026-03-19 | 開始されました | Wells Fargo | Overweight |
| 2026-01-09 | 開始されました | Citigroup | Buy |
| 2025-12-17 | 開始されました | TD Cowen | Buy |
| 2025-12-09 | 開始されました | JP Morgan | Overweight |
| 2025-11-25 | 再開されました | Wedbush | Neutral |
| 2025-10-15 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | アップグレード | Stifel | Hold → Buy |
| 2025-06-30 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 開始されました | Wedbush | Outperform |
| 2022-04-27 | 開始されました | Goldman | Neutral |
| 2021-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-03 | 開始されました | Robert W. Baird | Outperform |
| 2021-12-02 | 開始されました | Oppenheimer | Outperform |
| 2021-10-19 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-25 | 開始されました | B. Riley Securities | Buy |
| 2021-03-03 | 開始されました | Barclays | Overweight |
| 2021-03-03 | 開始されました | Evercore ISI | Outperform |
| 2021-03-02 | 開始されました | Goldman | Sell |
| 2021-03-02 | 開始されました | Stifel | Buy |
すべてを表示
Vor Biopharma Inc (VOR) 最新ニュース
Form 4 Vor Biopharma Inc For: 5 October By Investing.com - Investing.com Canada
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
Vor Biopharma (Nasdaq:VOR)Stock Analysis - Simply Wall Street
Jefferies Maintains Vor Biopharma(VOR.US) With Buy Rating, Cuts Target Price to $48 - moomoo.com
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com India
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com Canada
Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push By Investing.com - Investing.com UK
VOR: Phase III MG trial enrollment complete; robust efficacy and market expansion plans underway - TradingView
Vor Biopharma (VOR) Completes Enrollment in Phase 3 Trial as Mar - GuruFocus
Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis - marketscreener.com
Vor Biopharma Inc. (VOR) Latest Press Releases & Corporate News - Yahoo Finance
Vor Biopharma (VOR) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VOR - MarketBeat
Vor Biopharma Stock Price Forecast. Should You Buy VOR? - StockInvest.us
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vor Biopharma Inc. (VOR) Stock Price, News, Quote & History - Yahoo Finance
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - sg.finance.yahoo.com
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - theglobeandmail.com
Vor Bio To Participate in Upcoming September Conferences - marketscreener.com
Vor Bio To Participate in Upcoming September Conferences - Yahoo Finance
Vor Biopharma Inc. (VOR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vor Biopharma (VOR) RA Capital-linked option yields 1,500 shares - Stock Titan
Why Did Vor Biopharma (VOR) Stock Drop After Its Latest Update? - Sahm
Vor (VOR) Snapshot: Adds 1.28% to Close at $23.36 on the Day; Key Range: Support at $22.19 and Resistance at $24.53 Frame the Range in the Latest ReadingHot Stock Picks - vinanet.vn
US and Canadian markets settled this week on a negative note, Two stocks to consider – LITH, VOR - kalkine.ca
How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift - simplywall.st
How Investors Are Reacting To Vor Biopharma (VOR) Sharply Narrowed Losses And Earnings Profile Shift - simplywall.st
Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - MarketBeat
Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake - Stock Titan
Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership - Stock Titan
Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright - MarketBeat
Verve Capital Limited (VOR) reports 6.3% stake in Vor Biopharma common stock - Stock Titan
Citi Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18 - webull.com
VOR Maintains Rating by Wedbush -- Price Target Raised to $27.00 - GuruFocus
Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - MarketBeat
Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings - MarketBeat
Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Vor Biopharma (VOR) Reports Improved Cash Position and Reduced L - GuruFocus
Vor Biopharma Reports Q2 2026 Financial Results in SEC Form 10-Q Filing - Kalkine Media
Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate - scanx.trade
Vor Biopharma (NASDAQ:VOR) Posts Earnings Results - MarketBeat
Vor Biopharma (VOR) Strengthens Cash Position Amid Unprofitable Operations - GuruFocus
VOR Stock Update: Telitacicept Advances Amid Mixed Financial Sig - GuruFocus
Vor Biopharma Shares Drop After Q2 Results - marketscreener.com
Vor Biopharma Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costs - TradingView
Vor Biopharma Inc (VOR) 財務データ
収益
当期純利益
現金流量
EPS
Vor Biopharma Inc (VOR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Aug 24 '26 |
Option Exercise |
3.74 |
1,500 |
5,604 |
1,500 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner |
Jul 16 '26 |
Sale |
19.75 |
213 |
4,207 |
4,501,882 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 22 '26 |
Sale |
15.77 |
165,150 |
2,604,416 |
2,402,095 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 20 '26 |
Sale |
15.77 |
171,963 |
2,711,857 |
2,567,245 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 17 '26 |
Sale |
16.28 |
458,411 |
7,462,931 |
2,739,208 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 15 '26 |
Sale |
16.01 |
53,644 |
858,840 |
3,197,619 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 14 '26 |
Sale |
15.97 |
153,735 |
2,455,148 |
3,251,263 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 13 '26 |
Sale |
16.15 |
530,610 |
8,569,352 |
3,404,998 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 10 '26 |
Sale |
15.75 |
828 |
13,041 |
3,935,608 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Apr 09 '26 |
Sale |
16.59 |
135,201 |
2,242,985 |
3,936,436 |
4.46%
大文字化:
|
ボリューム (24 時間):